Regeneron reports strong results with Dupixent driving growth; other sectors show mixed performance.

Biopharma company Regeneron delivered strong financial results, with its key drug Dupixent exceeding growth expectations. Meanwhile, Abbott faced challenges after its acquisition of Exact Sciences, and sectors like digital publishing, hospitality, and supermarkets experienced mixed or negative impacts. These results highlight Regeneron's robust position in biopharma amid varied industry performances, signaling potential for continued growth in its key products.

As of Oct 15, 2026 03:42 WIB, Regeneron Pharmaceuticals Inc (REGN) is trading at USD 780.50 with a 1-day gain of 3.64% on Pluang, reflecting strong investor interest despite a high sell order activity of 89%. Abbott Laboratories (ABT) is priced at USD 103.10, up 0.42% for the day, with a dominant buy order activity of 94%. Regeneron's market cap stands at $77.54 billion, highlighting its significant presence in the health sector.